<DOC>
	<DOCNO>NCT00627835</DOCNO>
	<brief_summary>The purpose study ass safety determine MTD ( maximal tolerate dos ) recommend dos neoadjuvant sorafenib ( BAY 43-9006 ) concurrent sorafenib , cisplatin radiation locally advance squamous cell carcinoma head neck ( SCCHN ) patient population .</brief_summary>
	<brief_title>Dose Escalation Trial Neoadjuvant Sorafenib Concurrent Sorafenib , Cisplatin Radiation Locally Advanced Squamous Cell Carcinomas Head Neck ( SCCHN )</brief_title>
	<detailed_description>Squamous cell carcinoma head neck relatively common malignancy Canada United States . Despite advancement make demonstration improve outcomes concurrent platinum base chemotherapy radical radiation locally advance SCCHN , approximately 50 % case recur . The current treatment locoregionally recurrent/metastatic SCCHN palliative intent , median survival population 6-8 month . Thus improvement current backbone treatment locally advance SCCHN , platinum base chemotherapy radical radiation , desperately need . This non-randomized , open-label , phase I dose escalation trial neoadjuvant Sorafenib concurrent Sorafenib , Cisplatin radiation locally advance squamous cell carcinoma head neck ( SCCHN ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Treatment Group 1 ( Cohorts 1 &amp; 2 ) Radiation Sorafenib Only . 1 . Previously untreated squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Histological cytological confirmation require . The disease must consider potentially curable radiation . 2 . Stage III IV disease ( UICC/AJCC classification , 6th edition ) 3 . Age ≥18 4 . Patients concurrent cisplatinum contraindicate due poor patient tolerance ( significant weight loss &gt; 10 % body weight , mild renal dysfunction , ototoxicity , neuropathy , age &gt; 70 ) yet deem fit radical radiation . 5 . Signed write consent . 6 . Availability followup treatment . 7 . If patient fertile he/she aware risk become pregnant father child use adequate contraception ( oral contraception , IUD , diaphragm spermicide male condom spermicide ) throughout therapy least 2 week therapy . 8 . Life expectancy great 6 month Treatment group 2 ( Cohorts 3 5 ) Radiation , Sorafenib Cisplatin . 1 . Previously untreated squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Histological cytological confirmation require . The disease must consider potentially curable combine chemoradiation . 2 . Stage III IV disease ( UICC/AJCC classification , 6th edition ) 3 . Age ≥18 . 4 . Signed write consent . 5 . Availability followup treatment . 6 . If patient fertile , he/she aware risk become pregnant father child use adequate contraception ( oral contraception , IUD , diaphragm spermicide male condom spermicide ) throughout therapy least 3 month therapy . 7 . Life expectancy great 6 month Treatment Group 1 ( Cohorts 1 &amp; 2 ) Radiation Sorafenib Only . 1 . ECOG performance status 3 4 2 . Absolute neutrophil count &lt; 1.0 X 109/L , platelet count &lt; 100 X 109/L hemoglobin &lt; 90 g/L . 3 . Serum bilirubin ≥1.5 time ULN AST/ALT ≥ 2.5 time ULN . 4 . Calculated creatinine clearance ( CockcroftGault ) &lt; 40 mL/min . For patient calculated creatinine clearance borderline , GFR may estimate nuclear renogram creatinine clearance ≥ 40 mL/min eligible . 5 . Uncontrolled hypertension despite adequate antihypertensive medication 6 . Bleeding diathesis 7 . Significant intercurrent illness interfere radiation therapy trial HIV infection , pulmonary compromise , active significant alcohol abuse , active infection febrile illness 8 . Any history myocardial infarction , congestive heart failure ( NY Heart Association Class 3 4 ) , history ventricular arrhythmia , angina active coronary heart disease within 6 month . 9 . Primary cancer nasal paranasal cavity , nasopharynx . 10 . Evidence distant metastasis . If base best available clinical evidence investigator wish enroll subject trial , discussion documentation one principal investigator require . 11 . Weight loss great 25 % usual body weight 3 month precede trial entry . 12 . High risk poor compliance therapy followup assess investigator . 13 . Pregnant lactating woman . 14 . Prior radiation therapy great 30 % bone marrow 15 . Prior experimental therapy cancer within 30 day enter trial . 16 . Prior radiation head neck cancer . 17 . Patients prior cancer , except : diagnosed five year ago evidence disease recurrence clinical expectation recurrence le 5 % ; successfully treat nonmelanoma skin cancer ; carcinoma situ cervix . However , patient previous invasive breast cancer , prostate cancer melanoma exclude . Treatment group 2 ( Cohorts 3 5 ) Radiation , Sorafenib Cisplatin . 1 . ECOG performance status 3 4 2 . Absolute neutrophil count &lt; 1.0 X 109/L , platelet count &lt; 100 X 109/L hemoglobin &lt; 90 g/L . 3 . Serum bilirubin ≥1.5 time ULN AST/ALT ≥ 2.5 time ULN . 4 . Calculated creatinine clearance ( CockcroftGault ) &lt; 55 mL/min . For patient calculated creatinine clearance borderline , GFR may estimate nuclear renogram creatinine clearance ≥ 55 mL/min eligible . 5 . Uncontrolled hypertension despite adequate antihypertensive medication 6 . Bleeding diathesis 7 . Significant intercurrent illness interfere chemotherapy radiation therapy trial HIV infection , cardiac insufficiency , pulmonary compromise , active significant alcohol abuse , active infection febrile illness , 8 . Any history myocardial infarction , history ventricular arrhythmia , angina active coronary heart disease within 6 month . Significant cardiac disease result inability tolerate intravenous fluid load require administration cisplatin . 9 . Primary cancer nasal paranasal cavity , nasopharynx . 10 . Evidence distant metastasis . If base best available clinical evidence investigator wish enroll subject trial , discussion documentation one principal investigator require . 11 . Symptomatic peripheral neuropathy ≥ grade 2 . 12 . Clinically significant sensorineural hearing impairment may exacerbate cisplatin ( audiometric abnormality without correspond clinical hearing impairment ground exclusion ) 13 . Weight loss great 20 % usual body weight 3 month precede trial entry . 14 . High risk poor compliance therapy followup assess investigator . 15 . Pregnant lactating woman . 16 . Prior radiation therapy great 30 % bone marrow 17 . Prior experimental therapy cancer within 30 day enter trial . 18 . Prior radiation head neck cancer . 19 . Patients prior cancer , except : diagnosed five year ago evidence disease recurrence clinical expectation recurrence le 5 % ; successfully treat nonmelanoma skin cancer ; carcinoma situ cervix . However , patient previous invasive breast cancer , prostate cancer melanoma exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>head neck</keyword>
	<keyword>Neoadjuvant Sorafenib Concurrent Sorafenib , Cisplatin Radiation</keyword>
</DOC>